Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hemagen's HIV-survivor test trial in final stage

This article was originally published in Clinica

Executive Summary

Trials of Hemagen's HIV-survivor test are about to start in France and Brazil. The test identifies anti-B-2 microglobulin, antibody associated with long-term survivors (see Clinica No 687, p 14). Hemagen is producing the assays which will be used to test 10,000 patients and controls in Sao Paulo, Brazil, and Marseille, France, by the end of August.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts